Christopher Randolph
Content created by Dr. Christopher Randolph, Chief Scientific Officer, WCG MedAvante-ProPhase
-
Read FlipbookCNS Drugs Take Longer to Develop, Win Approval
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
-
Read FlipbookDetecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility
Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer’s disease (AD).
-
Read FlipbookIdentifying Elevated Rates of CDR Scoring Errors
The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.
-
Read FlipbookIncreased Signal Detection in Alzheimer's Disease Clinical Trials
This study investigated the impact of lag time on error rates for commonly used Alzheimer’s disease COAs, as well as the degree to which administration attenuated error rates associated with lag time.
-
Read FlipbookRBANS as a Useful Outcome Measure in Prodromal AD Trials
The goal of the present study was to examine the potential utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in prodromal AD trials.
-
Read FlipbookProspective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain
The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.
-
Read FlipbookAcute Clinical Predictors of Symptom Recovery in Emergency Department Patients with Uncomplicated Mild Traumatic Brain Injury or Non-Traumat
The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.
-
Read FlipbookIs cognitive decline measurable in preclinical Alzheimer’s disease?
As Alzheimer’s disease (AD) drug development moves to earlier, preclinical stages of disease, clinicians, trialists, and regulators have wrestled with the question of how to detect cognitive change...
-
Read FlipbookA systematic review of potential long-term effects of sport-related concussion
Objective: Systematic review of possible long-term effects of sports-related concussion in retired athletes.
-
Read FlipbookRecommended cognitive outcomes in preclinical Alzheimer’s disease - Consensus statement from the European Prevention of Alzheimer’s Dementia
The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer’s disease.
-
Read FlipbookMultiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development
This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies...
-
Loading More...
